Q1 2026 Earnings Estimate for Theravance Biopharma, Inc. (NASDAQ:TBPH) Issued By Zacks Research

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities research analysts at Zacks Research increased their Q1 2026 EPS estimates for Theravance Biopharma in a report released on Monday, April 15th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will post earnings of $0.29 per share for the quarter, up from their prior forecast of $0.25. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.83) per share.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $17.57 million for the quarter, compared to the consensus estimate of $17.49 million. Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%.

A number of other research firms have also recently commented on TBPH. Evercore ISI cut shares of Theravance Biopharma from an “outperform” rating to an “inline” rating in a research note on Monday, January 8th. BTIG Research assumed coverage on shares of Theravance Biopharma in a report on Friday, April 12th. They set a “buy” rating and a $21.00 price objective on the stock.

Theravance Biopharma Trading Down 2.3 %

NASDAQ TBPH opened at $9.69 on Tuesday. The firm’s fifty day simple moving average is $8.96 and its two-hundred day simple moving average is $9.66. The firm has a market capitalization of $470.55 million, a P/E ratio of -9.99 and a beta of 0.36. Theravance Biopharma has a 12-month low of $8.21 and a 12-month high of $12.03.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in TBPH. Gerber LLC acquired a new position in Theravance Biopharma in the fourth quarter valued at approximately $112,000. Wellington Management Group LLP boosted its holdings in Theravance Biopharma by 68.0% during the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after buying an additional 116,164 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Theravance Biopharma by 6.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 286,291 shares of the biopharmaceutical company’s stock valued at $3,218,000 after buying an additional 16,506 shares in the last quarter. Barclays PLC increased its holdings in Theravance Biopharma by 253.9% in the fourth quarter. Barclays PLC now owns 82,357 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 59,088 shares in the last quarter. Finally, Newtyn Management LLC raised its position in shares of Theravance Biopharma by 3.2% in the fourth quarter. Newtyn Management LLC now owns 1,900,000 shares of the biopharmaceutical company’s stock worth $21,356,000 after acquiring an additional 58,440 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.